KAIST 생명과학과동창회
  • News & Events
  • News

News

Antibiotic tolerance study paves way for new treatments


A new study identifies a mechanism that makes bacteria tolerant to penicillin and related antibiotics, findings that could lead to new therapies that boost the effectiveness of these treatments.


Antibiotic tolerance is the ability of bacteria to survive exposure to antibiotics, in contrast to antibiotic resistance, when bacteria actually grow in the presence of antibiotics. Tolerant bacteria can lead to infections that persist after treatment and may develop into resistance over time.

The study in mice, “A Multifaceted Cellular Damage Repair and Prevention Pathway Promotes High Level Tolerance to Beta-lactam Antibiotics,” published Feb. 3 in the journal EMBO Reports, reveals how tolerance occurs, thanks to a system that mitigates iron toxicity in bacteria that have been exposed to penicillin.


“We’re hoping we can design a drug or develop antibiotic adjuvants that would then basically kill off these tolerant cells,” said senior author Tobias Dörr, assistant professor of microbiology in the Weill Institute for Cell and Molecular Biology in the College of Agriculture and Life Sciences.


Co-authors included Ilana Brito, the Mong Family Sesquicentennial Faculty Scholar and assistant professor in the Meinig School of Biomedical Engineering in the College of Engineering, and Lars Westblade, associate professor of pathology and laboratory medicine at Weill Cornell Medicine.


Some bacteria, including the model bacterium used in the study, Vibrio cholerae, which causes cholera in humans, are remarkably tolerant to penicillin and related antibiotics, known as beta lactam antibiotics. It has been known for a long time that beta-lactam antibiotics break down bacterial cell walls, but how bacteria survive loss of their cell walls was poorly understood.


In the study, the researchers developed a V. cholerae mutant that lacked a two-component damage repair response system that controls a gene network encoding diverse functions. Without the system, known as VxrAB, when the cell wall is damaged by antibiotics, the transfer of electrons across the cell membrane goes awry, leading to electrons ending up on the wrong molecules. This misdirection causes hydrogen peroxide to accumulate in the cell, which changes the oxidation state of cellular iron and disrupts signals for the cell to tell how much iron it has.   


In the presence of hydrogen peroxide, the mutant bacteria cannot sense how much iron has been acquired, and it behaves as if it is iron-starved and seeks to acquire more iron. Left unchecked, these circumstances cause iron toxicity, which will kill the cell, according to the experiments the researchers conducted. In further tests with mutant V. cholerae bacteria, both in test tubes and in mice, the researchers showed that reducing the influx of iron increased the bacteria’s tolerance to beta lactams.


Fortunately for normal V. cholerae, exposure to antibiotics and the breakdown of the cell’s walls activate the VxrAB system, which works to repair cell walls and downregulates iron uptake systems, and thereby creates antibiotic tolerance. More study is needed to understand what triggers the VxrAB system in the presence of beta-lactam antibiotics.


The research opens the door for developing new drugs that could be combined with antibiotics to exploit oxidative damage and iron influx in tolerant bacteria. In future work, the researchers will search for parallel mechanisms of tolerance in other bacterial pathogens.


Jung-Ho Shin, a postdoctoral researcher in Dörr’s lab, is the paper’s first author. Co-authors include researchers from the Korea Advanced Institute of Science and Technology, the Korea Advanced Institute of Science and Technology, and the Intelligent Synthetic Biology Center in Korea.

The study was funded by the National Research Foundation of Korea and the National Institutes of Health.


https://news.cornell.edu/stories/2021/02/antibiotic-tolerance-study-paves-way-new-treatments

https://www.miragenews.com/antibiotic-tolerance-study-paves-way-for-new-516267/



List of Articles
번호 제목 글쓴이 날짜 조회 수
370 [김찬혁 교수님] 6월 ‘이달의 과학기술인상’ 수상 생명과학과 2023.06.08 274
369 [김찬혁 교수님] 말기 고형암 표적 2세대 면역치료제 개발​ 생명과학과 2023.04.20 388
368 [김찬혁 교수님] 서울대병원, '꿈의 항암제' CAR-T 임상1상 본격 돌입 생명과학과 2022.02.04 600
367 [김찬혁 교수님] 카이스트, 면역관문 신호 극복하는 차세대 CAR-T 세포 치료제 개발 생명과학과 2021.11.24 630
366 [김찬혁, 정원석 교수님] 심각한 염증 부작용 없앤 새로운 알츠하이머병 치료제 개발​ 생명과학과 2022.08.22 628
365 [김학성 교수님, 김홍식 박사님] 암세포에만 약물 전달 가능한 클라트린 조립체 개발​ 생명과학과 2023.03.15 378
364 [김학성 교수님] 알츠하이머 조기 진단하는 센서단백질 디자인하다​ 생명과학과 2023.12.08 206
363 [김학성 교수님] 카이스트, 거대 단백질 구조체를 레고 블록 쌓듯 조립하는 기술 개발 생명과학과 2021.11.24 682
362 [김학성 명예교수님] 2023 효소공학상(Enzyme Engineering Award) 수상​ 생명과학과 2023.08.24 228
361 [대덕넷] 노화억제 비밀 밝혀낸 김태국 교수...연구성과 집대성 '풀베팅' 과사무실 2006.06.12 14175
360 [대덕넷] 생명과학과 정종경교수... 과기부 2분기 우수과학자 10인 선정 과사무실 2007.09.04 13651
359 [대덕넷] 임대식 교수 이달의 과기인상 수상 과사무실 2004.08.30 13002
358 [대덕넷] 임대식 교수"癌 억제하는 유전자 기능 밝혀졌다" 과사무실 2004.02.06 13532
357 [대덕넷] 제넥셀, 日 신약개발업체서 외자유치 과사무실 2005.03.31 10922
356 [동아일보] 김은준 교수 젊은 과학자상 수상 과사무실 2004.12.27 11931
355 [동아일보] 노화억제 신약후보물질 개발…김태국 교수팀 과사무실 2006.06.12 11314
354 [동아일보] 뇌 신호전달 작동물질 첫 발견-김은준교수팀 과사무실 2006.04.20 12022
353 [동아일보] 위암 당뇨 ‘맞춤 치료’ 길 열린다…SNP 지도 첫 완성 과사무실 2006.12.14 13357
352 [동아일보] 한국 과학에 세계가 또 놀라다 -정종경교수팀 과사무실 2006.05.04 14541
351 [동아일보] 혈관형성 촉진제 이용 만성 신장질환 고쳐요-고규영교수 과사무실 2006.08.03 11574
Board Pagination Prev 1 2 3 4 5 6 7 8 9 10 ... 22 Next
/ 22